Loading
Life sciences · Journal article
Frontiers in Immunology · November 3, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Metastatic colorectal cancer (mCRC) remains a major cause of cancer-related morbidity and mortality worldwide. Its systemic treatment has evolved from conventional cytotoxic chemotherapy toward biomarker-driven targeted therapy and immunotherapy. Advances in molecular profiling have refined patient selection for anti-EGFR and anti-VEGF therapies and have enabled the development of treatments directed against BRAF V600E, KRAS G12C, HER2 amplification, and other actionable alterations. In parallel, immune checkpoint inhibitors have transformed the management of microsatellite instability-high/mismatch repair-deficient mCRC, whereas microsatellite-stable disease remains largely resistant to immunotherapy and continues to require rational combination strategies. Despite these advances, primary and acquired resistance, dynamic clonal evolution, and the immunosuppressive tumor microenvironment remain major barriers to durable disease control. Circulating tumor DNA and multidimensional molecular profiling are increasingly being explored to monitor treatment response, identify emerging resistance, and guide sequential therapy. This review summarizes recent advances in targeted therapy and immunotherapy for mCRC and discusses priorities for developing adaptive, biomarker-driven treatment strategies.